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ABSTRACT 
The incidence of Neonatal Abstinence Syndrome (NAS) is abounding in hospitals 
across the nation due to the recent surge in opioid abuse. This thesis explores the 
variation in protocols and guidelines used by healthcare practitioners concerning NAS. 
This study consisted of a literature review as well as observations and interviews with 
healthcare practitioners in Neonatal Intensive Care Units (NICUs). The literature review 
revealed there has been a greater increase in NAS among rural areas, and there is 
currently no national standardized protocol for the treatment of NAS. Field notes taken 
during the interviews and observations confirmed the literature in that each NICU’s 
protocol varied, although they were similar in many aspects. Five main themes were 
identified from the field notes, as well. In conclusion, it may prove beneficial to look into 
the development process of similar disease protocols such as Fetal Alcohol Syndrome 
(FAS) to gain insight to aid in the creation of a standardized protocol for NAS.        
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INTRODUCTION 
The opioid epidemic is one of the most serious issues facing America today. Over 
the past decade or so, as addiction rates have skyrocketed and garnered the attention of 
media outlets both local and national, several questions have emerged about the origins of 
and possible solutions to the crisis. While it is occurring across race, class, and 
geographic lines, the opioid problem is affecting populations well outside the 
stereotypical scope of Americans’ traditional views of drug abuse, as it has taken root in 
predominantly white rural communities and branched out into suburban, middle class 
areas (Cicero, Ellis, Surratt, & Kurtz, 2014). The effects of the crisis are being felt across 
the nation but perhaps most strongly in the waiting rooms of America’s rural hospitals, 
where people are being treated for overdoses. Additionally, a phenomenon often 
overlooked in news stories is the occurrence of Neonatal Abstinence Syndrome (NAS). 
NAS is a “drug-withdrawal syndrome that most commonly occurs after in utero exposure 
to opioids” and “manifests in the first few days of life as hypertonia, autonomic 
instability, irritability, poor sucking reflex, impaired weight gain, and less commonly, 
seizures” (Tolia et al., 2015, p. 2118-2119). According to data collected in 2014, a 
newborn was diagnosed with NAS every fifteen minutes, which resulted in a total of 
approximately 32,000 infants being diagnosed (Honein, Boyle, & Redfield, 2019). The 
headlines and soundbites are loud, but how did we get here?   
In 1990 the president of The American Pain Society, Dr. Max Mitchell, claimed 
that doctors were not adequately treating patients’ pain. Mitchell stated that “addiction is  
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rare in medical patients with no history of addiction,” an observation based on a single 
publication in 1980 that included no information on how it was conducted (Porter & Jick, 
1980, p. 1). One year after Dr. Mitchell’s declaration, The American Pain Society issued 
new quality assurance standards for the treatment of acute pain and cancer pain. A decade 
passed, and the medical community’s philosophy of pain treatment continued to evolve. 
To help physicians overcome their “opiophobia”, physician-spokespersons for 
opioid manufacturers informed prescribers that addiction was rare and cited flawed 
studies to emphasize the claim that the risk of addiction was less than 1% (Kolodny et al., 
2015). Between 1996 and 2002, Purdue Pharma funded more than 20,000 pain-related 
educational programs and issued a campaign to encourage long-term use of opioids for 
chronic non-cancer pain. In addition, they gave financial contributions to the American 
Pain Society, the American Academy of Pain Medicine, the Federation of State Medical 
Boards, the Joint Commission, and many others. As a result, these organizations began 
pushing for “more aggressive identification and treatment of pain, especially use of 
opioid pain relievers” (Kolodny et al., 2015, p. 562).  
 In 2000, The Joint Commission, the nation’s leading health care accreditation 
group, released standards for organizations to better treat patients with pain by 
quantitatively measuring pain on a ten-point scale (Baker, 2017). Essentially, pain 
became known as the “fifth vital sign,” in addition to body temperature, pulse rate, 
respiration rate, and blood pressure (Baker, 2017). Hospitals began using treatment 
protocols and algorithms based on patients’ responses to questions regarding their pain 
level. This became a cause for concern among health care practitioners as the incidence 
of over-sedation by opioids increased from 11.0 to 24.5 per 100,000 inpatient hospital 
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days after the numerical pain treatment algorithm was put in place (Baker, 2017). 
Realizing the implications of the numerical pain scale, The Joint Commission took 
measures to fully remove the phrase “pain as the fifth vital sign” from the accreditation 
standards manual by 2004. In 2009, The Joint Commission also removed the previous 
standard that all patients’ pain levels be measured, regardless of the nature of their visit, 
except for patients in behavioral health care. However, a study found that from 2009 to 
2010, physicians prescribed opioids, often in high doses, in more than 50% of 1.14 
million adult nonsurgical hospital admissions (Herzig, Rothberg, Cheung, Ngo, & 
Marcantonio, 2014).  
The Joint Commission continued to modify the pain treatment protocol, and in 
2011, placed an emphasis on the range of options, both pharmacological and 
nonpharmacological, that could be used in treating pain. Today, The Joint Commission is 
still working to mitigate the effects of the 2000 standards. Draft standards were released 
in 2017 with recommendations to consider patients’ psychosocial background as well as 
include the patient’s input in treatment planning and closely monitor the use of 
prescription opioids (Baker, 2017). Despite The Joint Commission’s efforts, opioid 
addiction rates have continued to rise unabated.   
In the United States from 2000 to 2012, the rates of Neonatal Abstinence 
Syndrome (NAS) and maternal opioid abuse increased nearly 5-fold (Villapiano, 
Winkelman, Kozhimannil, Davis, & Patrick, 2017). Perhaps no one could have predicted 
the harmful effects that the alarming increase in opioid addicts would have on the future 
generations of infants. NAS is a fairly new phenomenon, and there is still a plethora of 
new research that needs to be conducted to better the lives of both mother and baby 
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dealing with the devastating effects of drug addiction. This study investigates healthcare 
practitioners’ treatment of NAS in order to provide insight to aid in the creation of a 
national standardized treatment protocol for NAS. 
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LITERATURE REVIEW 
Opioid Definition  
 According to the National Institutes of Health (NIH), opioids are a class of drugs 
that activate opioid receptors throughout the nervous system that result in relief from 
pain. Opioids include illegal street drugs such as heroin, synthetic drugs such as fentanyl, 
and legal prescription drugs used for pain relief (NIH, n.d.). The most commonly 
prescribed opioids include methadone, codeine, hydrocodone, oxycodone, propoxyphene, 
fentanyl, tramadol, hydromorphone, morphine, and levorphanol (Mistry, Bawor, Desai, 
Marsh, & Samaan, 2014). Opioids are prescribed for pain management in both acute and 
chronic conditions. These include non-cancer chronic pain, post-surgical treatment, and 
musculoskeletal pain. Because opioids belong to an addictive class of narcotics, abuse 
often leads to “the development of tolerance, dependence, and overdose” (Mistry et al., 
2014, p. 156).   
History of the Opioid Epidemic  
Deaths by opioid overdose have skyrocketed since the national standards urged 
physicians to treat pain by use of prescription opioids. Since 1999, the number of deaths 
from prescription opioid overdose have quadrupled, surpassing the number of deaths 
involving cocaine and heroin combined by 2007 (Keyes, Cerdá, Brady, Havens, & Galea, 
2014). Drug addiction as a public health problem itself is not a new phenomenon, but the 
sources of that addiction have changed dramatically. Research indicates that increased 
availability and ease of access are significant contributors to this epidemic (Keyes et al., 
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2014). Pressured by evolving treatment protocols, physicians were tasked with better 
treatment of pain. As a result, there was a marked increase in the availability of 
prescription drugs. For example, methadone sales increased thirteen-fold between 1997 
and 2007 (Keyes et al., 2014). By 2010, there were enough prescription opioids to 
administer five milligrams of hydrocodone every four hours to every single adult in the 
United States for one month (Keyes et al., 2014). As the number of people with a 
prescription for an opioid medication has risen, access to such medications has become 
proportionately easier. Researchers have found that most nonmedical opioid users obtain 
the drugs from friends, family members, or street dealers (Keyes et al., 2014).  
Opioids Across the Rural - Urban Continuum    
The increase in opioid deaths has been nationwide, but there are notable regional 
pockets of even greater incidences of overdose. Largely rural populations in states such 
as Kentucky, West Virginia, Alaska, and Oklahoma have experienced the opioid crisis to 
a more severe extent than others (Keyes et al., 2014). The reasons for this phenomenon 
are unclear, but researchers have begun to identify some of the risk factors that explain 
why rural populations are more likely to abuse prescription opioids. In concert with the 
national trend, the availability of prescription opioids has increased throughout rural areas 
in recent years. OxyContin™, in particular, was more heavily marketed in rural areas 
surrounding Appalachia (Keyes et al., 2014), which may explain some of the increase. A 
generally higher level of chronic pain itself may also be an explanation (Keyes et al., 
2014). Rural populations also tend to be more elderly than urban populations, which 
would be associated with more chronic pain and more chronic pain-related opioid 
prescriptions (Keyes et al., 2014). Finally, rural populations also experience more chronic 
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pain and injury related to rural industries, such as coal mining and other heavy labor 
professions (Keyes et al., 2014). According to Keyes et al. (2014), there also seems to be 
an emigration of young adults from rural areas. For example, West Virginia’s percentage 
of adults aged older than 65 is twice that of those aged 18 to 24 (Keyes et al., 2014). This 
demographic phenomenon has two effects that work in concert. Primarily, this creates an 
aging workforce which leads to poor economic infrastructure and development. 
Communities with substandard economies and workforces may become more vulnerable 
and succumb to the use of nonprescription opioids, along with other substances. The 
secondary effect may lead to an increase in opioid abuse among the young adults who 
stay in these rural communities. Young adults who remain in these areas may have a 
greater risk of drug abuse and may be more likely to become drug dependent at a young 
age (Keyes et al., 2014).  
Although the specific reasons for increased drug abuse rates among rural areas is 
unclear, there is an interesting political correlation. According to Monnat’s (2016) study, 
Trump over performed in the 2016 Presidential Election in counties that experienced the 
highest drug, alcohol, and suicide mortality rates. The study also noted that these “deaths 
of despair” are higher among non-Hispanic whites and that it has raised the overall 
mortality rate for middle-aged non-Hispanic whites, most notably those lacking a college 
degree living in small cities and rural areas. Economic distress and the presence of a 
working class appear to account for the relationship between Trump’s success in these 
areas with high rates of “deaths of despair”. These areas include Appalachia, the 
Industrial Midwest, and New England. All of these areas have experienced increased 
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unemployment rates in manufacturing and are considered economically distressed 
(Monnat, 2016).    
Compared to urban areas, communities in rural areas tend to have larger families 
and higher fertility rates (Keyes et al., 2014). Taking this into account and the increase in 
opioid abuse among rural populations, one might reasonably speculate that there has been 
an increase in Neonatal Abstinence Syndrome (NAS) in these communities as well. The 
occurrence of NAS across the United States nearly tripled from 2000 to 2009, and 
patients are requiring longer inpatient treatments with the median length of stay 
increasing from 13 to 19 days from 2004 to 2013 (Tolia et al., 2015). As with the greater 
increase in opioid abuse among rural areas, there also seems to be a greater increase in 
NAS among rural communities when compared to urban areas. From 2004 to 2013, NAS 
occurrences in rural infants increased from 1.2 to 7.5 per 1,000 hospital births whereas 
NAS occurrences in urban infants increased from 1.4 to 4.8 per 1,000 hospital births 
(Villapiano et al., 2017). In correlation, deliveries complicated by maternal opioid abuse 
increased more drastically among rural mothers (1.3 to 8.1 per 1,000 hospital deliveries) 
compared to urban mothers (1.6 to 4.8 per 1,000 hospital deliveries) (Villapiano et al., 
2017). Although there has been an increase in nonmedical prescription opioid morbidity 
and mortality across all areas, these phenomena have been concentrated in states with 
largely rural populations (Keyes et al., 2014). The occurrence of maternal opioid use and 
NAS have increased disproportionately in rural counties when compared to urban 
counties as well (Villapiano et al., 2017). 
This drastic comparison emphasizes the need for better healthcare and drug 
prevention measures in rural communities across the United States. Specifically, rural 
 9 
counties are in dire need of hospitals with the capability of caring for and treating opioid 
affected mothers and infants (Villapiano et al., 2017). Currently, there is no standard 
treatment protocol for NAS, and treatments are varied in children’s hospitals across the 
United States (Patrick, Kaplan, Passarella, Davis, & Lorch, 2014).  
Nonpharmacological Treatments 
While a standardized treatment protocol is lacking, most all hospitals use 
nonpharmacological measures as a first line of treatment. These treatments alone may 
successfully treat the neonate in mild cases of withdrawal. Nonpharmacological 
treatments are “easily acceptable, less expensive, and less controversial” (Kocherlakota, 
2014, p. e553). The goal is to promote an environment of low stimulation to help calm 
the infant and minimize withdrawal symptoms. Swaddling is very important in keeping 
the infant calm and undisturbed. It is shown to decrease stimulation and crying and 
promote good sleeping habits. Skin-to-skin contact and pacifiers may also help soothe the 
child. Trained volunteer cuddlers are used in many hospitals to hold and comfort infants 
when family members and nurses are unable to do so. This human touch is especially 
important for babies born addicted to drugs such as opioids (Hilton, 2018). There are also 
nontraditional treatments such as massage therapy, music therapy, and non insertive 
acupuncture. Studies show that active maternal participation is the “best 
nonpharmacologic care” (Kocherlakota, 2014, e553). It is very important that the mother 
be treated with respect and that healthcare practitioners possess a nonjudgmental attitude 
towards the mother. If the mother feels like she is not being judged for the choices she 
has made, she may be more likely to participate in the care of her child. Supportive care 
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is essential in properly treating the infant and can lead to an earlier discharge from the 
hospital as well (Kocherlakota, 2014).  
Rooming-In 
Perhaps one of the most effective nonpharmacological treatments for opioid 
exposed infants and NAS is the rooming-in approach. Rooming-in occurs when the 
mother stays in the same room with her baby throughout the length of the hospital stay. 
Rooming-in of both mother and baby has remarkably profound benefits for both parties 
involved; it is a major part in the baby’s recovery and decreases the severity of 
withdrawal symptoms (Abrahams et al., 2007). The traditional method of treating NAS 
has been a two-fold approach involving a low-stimulation environment with feeding of a 
high calorie formula and administration of a narcotic or central nervous system 
suppressant aimed at decreasing the infant’s withdrawal symptoms. It has often been 
deemed necessary that the mother and infant be separated so that the infant can be closely 
monitored and observed; however, separation of mother and baby in normal situations 
can lead to detrimental outcomes including difficulties in bonding and attachment and 
can even result in abandonment. These issues are already closely associated with mothers 
who experience substance abuse (Abrahams et al., 2007). According to Abrahams et al. 
(2007), opioid exposed infants who roomed-in with their mothers were more likely to 
have a decreased length of stay in the hospital and were more likely to go home in the 
custody of their mothers. These infants were also less likely to need treatment for NAS 
(Abrahams et al., 2007). Rooming-in helps the mother feel more involved and also 
facilitates the act of breastfeeding which is readily encouraged, if possible. Breastfeeding 
may “decrease the incidence of NAS, the need for pharmacological treatment, and the 
 11 
length of the hospital stay” (Kocherlakota, 2014, p. 555). However, breastfeeding is not 
conducive if the mother has illicit drug and/or polydrug abuse or is infected with HIV 
(Kocherlakota, 2014). Overall, the rooming-in of mother and baby is an effective tool that 
should be used when possible and helps both individuals transition more easily into their 
new lives.  
Infant Seat 
There are several hospitals that are using a new, innovative technology that 
soothes the infant by simply placing him/her in an infant seat. It is called the 4moms 
mamaRoo and includes five different settings. These settings include car ride, kangaroo, 
tree swing, rock-a-bye, and wave. The seat bounces up and down and sways side to side 
which closely mimics the soothing sensation of being rocked. Through a pilot study 
conducted by the National Perinatal Association (NPA) and 4moms, researchers 
concluded that babies were more physiologically stable after thirty minutes in the swing. 
The babies had lower heart and respiratory rates and were in calmer behavioral states. 
Healthcare practitioners have advocated that mamaRoo is an effective 
nonpharmacological treatment for opioid exposed infants and those with NAS suffering 
with withdrawal symptoms. This is a great tool to help ease the discomforts of 
withdrawal and soothe the babies, especially when the parents, other family members, 
nurses, or volunteers are unavailable to comfort the infant. The mamaRoo is currently in 
375 hospitals across the nation (4moms & NPA, 2018).   
Criminalization  
There is currently a major controversy over the criminalization of pregnant 
women with substance abuse history. The first obstacle is accurate identification of in 
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utero drug exposure. There are many methods of identification including interview, self-
administered questionnaires, intake history, urine testing of mother and infant, and hair 
and meconium testing of the infant. Self-reporting is often a difficult task for many 
mothers for fear of involvement of Child Protective Services (CPS) and/or because it is 
socially unacceptable. There is also the issue of how society sees maternal drug use. 
Some view it as a public health crisis that needs compassion and understanding while 
others see it as a criminal act that deserves legal punishment. However, both the Supreme 
Court and the medical field see addiction as a disease (Lester, Andreozzi, & Appiah, 
2004). According to Lester et al. (2004), there were no statutes criminalizing drug use 
during pregnancy; therefore, many courts in the past have prosecuted women under child 
abuse, assault, murder, drug dealing, or delivery of drugs to a minor charges. However, 
according to the Guttmacher Institute, as of February 1, 2019, there are twenty-three 
states and the District of Columbia that consider substance abuse during pregnancy as 
child abuse, and three consider it grounds for civil commitment. Even if the mother is not 
criminally prosecuted, CPS can remove the child from the mother based on positive 
toxicology screens at the time of birth or confirmed reports of drug use in the home 
(Lester et al., 2004). After the child has been removed, CPS is required to ensure that the 
mother receives the opportunity for treatment for her substance abuse addiction through a 
plan formulated by the court system. If the mother refuses to comply, custody rights can 
be terminated, and the child will be eligible for adoption. Although every state has 
variations of laws mandating the report of child abuse and neglect, not every state has a 
law mandating the report of drug use during pregnancy (Lester et al., 2004). However, 
there are twenty-five states and the District of Columbia that require reporting of 
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suspected prenatal drug use by healthcare professionals. Eight states require them to drug 
test those individuals suspected of prenatal drug use (Guttmacher Institute, 2019). While 
it is a complex battle, many states are leaning towards treatment of the mother. Nineteen 
states have either created or funded drug treatment programs targeted specifically for 
pregnant women, and seventeen states and the District of Columbia have laws giving 
priority to pregnant women for state-funded drug treatment programs (Guttmacher 
Institute, 2019).  
Research  
Despite the increase in opioid addiction rates and subsequent rise in the number of 
NAS diagnoses, there is a lack of published research concerning this disease. Hospitals 
across the nation are in need of a standardized treatment protocol for NAS and proper 
education and funding for nonpharmacological treatment options. Community resources 
should also be made more available to mothers recovering from addiction, and if these 
resources are lacking in a community, arrangements should be attempted to help both 
mother and baby. Perhaps research could be conducted to see which types of community 
resources are most effective at assisting new parents struggling with addiction. 
Healthcare practitioners are needed in the development of a protocol, and their insight 
and knowledge is crucial in creating a protocol that will be effective and implemented to 
the fullest extent. These gaps in the literature led me to ask the question: What treatment 
protocols, community resources, and advocacy are healthcare practitioners who serve 
patients (including those from rural areas) in the South employing to better treat the 
influx of patients with NAS? There also seems to be a disconnect between the various 
national medical organizations and the healthcare practitioners who are actually 
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diagnosing and treating these infants. There are several organizations that have published 
guidelines in treating this disease, yet the protocols vary in hospitals across the nation. 
How are healthcare practitioners navigating these protocols and implementing them in 
their practice? 
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METHODS 
 In conducting this research on healthcare practitioners’ treatment of Neonatal 
Abstinence Syndrome (NAS), I performed a comparative case study by observing in 
hospital Neonatal Intensive Care Units (NICUs) and interviewing healthcare practitioners 
who treat infants diagnosed with NAS. The comparative case study was conducted at two 
different urban hospital NICUs located in the southern United States that serve patients 
from across their states, including rural populations. The study involved observation, 
interviews, and document reviews. NICUs in the southern U.S. were chosen due to the 
recent increase of NAS occurrence among rural areas. Due to the lack of availability of 
many types of healthcare in rural areas, patients are often forced to seek treatment in 
larger, more urban cities, especially for the specialized care required from high risk 
pregnancies. An interview with a registered nurse who works in a rural NICU was also 
conducted.  
The documents obtained include hospital treatment protocols, NAS scoring 
sheets, and informational pamphlets on NAS. Although most, if not all, NICUs/hospitals 
have a treatment protocol for NAS, there is no standardized policy for treatment (Patrick 
et al., 2014). Several national medical organizations have released guidelines/position 
statements concerning the treatment of NAS. To supplement these sources, I conducted 
research to explore and investigate the various protocols being practiced in hospitals 
today and the effectiveness of the different policies.  
Before I could interview or observe in the NICUs, I submitted an abbreviated  
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application to the Institutional Review Board at the University of Mississippi. I submitted 
my application and was approved in early April of 2018. I was also required to submit an 
additional application to the External Review Board for the first NICU I observed in. 
This application was approved in late July right before I conducted my observations and 
interviews at this particular NICU.    
I spent a total of two days, approximately 12 hours, at the first NICU I observed. 
This NICU is a Level IV facility with 96 beds. I was referred to this specific 
neonatologist by my thesis advisor and contacted her through email. I shadowed the 
attending neonatologist and her team. The team consisted of the attending as well as a 
neonatal fellow, pediatric resident, two neonatal nurse practitioners, a dietitian, and a 
speech pathologist. I observed and took field notes when applicable during the morning 
rounds. During rounds, the team presented on each of their patients and made changes to 
the treatment plan based on any new findings that had been made since the previous 
day’s rounds. Afterwards, I sat with the residents and fellows in the resident workroom. 
The residents did their charting, and I asked several questions pertaining to NAS such as 
how the NAS scoring sheet worked and the medication they used if pharmacological 
treatment was needed. The following day, I conducted my interview with the 
neonatologist and asked several questions about NAS. We discussed the diagnostic 
process, pharmacological and nonpharmacological treatments, and the rate of occurrence. 
This particular hospital had 19 infants diagnosed with NAS in 2016 compared to 58 in 
2017. I also asked about the placement of the infants, whether they were placed in the 
NICU, nursery, with the mother, etc. I took field notes on a legal pad throughout the 
interview. Afterwards, I observed morning rounds again and saw the daily routine of the 
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NICU. Once morning rounds were complete, I shadowed the neonatal fellow and 
followed him as he went to deliveries. During my observation, I did not witness 
interactions between providers and babies specifically diagnosed with NAS. There were 
two patients that received narcotics and required the NAS scoring scale; however, this 
was due to prolonged ventilation, not intrauterine drug exposure.  
For the second hospital I observed, I spent a total of approximately 16 hours over 
two consecutive days in early August of 2018. This particular NICU is a Level IV facility 
with 98 beds. I chose this NICU because of the large rural population it serves, and I had 
also previously shadowed in this facility. I contacted the neonatologist through email. I 
was required to complete paperwork and submit a background check prior to my 
observation. I began the first day by shadowing a NICU nurse. I watched as she cared for 
her two patients and charted. She talked with me about my project and gave me several 
documents which included treatment protocols on NAS. She also gave me the pamphlet 
they provide to the parents of a baby diagnosed with NAS which explains how to care for 
the infant and create a low-stimulation environment. I then shadowed one of the attending 
neonatologists and his team on morning rounds. The team consisted of the neonatologist, 
a neonatal nurse practitioner, dietitian, as well as a fellow observer. I followed them 
throughout rounds and took notes when applicable. Afterwards, I got a chance to ask the 
attending several questions about NAS treatment and his research on this topic. I took 
field notes on a legal pad during the questioning. That afternoon, I was able to sit in on a 
care team meeting. The care team provides support for opioid-exposed infants and 
consists of many different professions including physicians, nurses, social workers, child 
life specialists, lactation consultants, and care providers. During the meeting, they 
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discussed the successes of the program and its progress, reviewed and edited a new 
parent information pamphlet, and presented results from an internal survey on Trauma 
Informed Care, an initiative to educate nurses about addiction and its effects on mothers. 
On the second day, I shadowed a lactation consultant who works for the care team. I 
interviewed her and asked the same questions I asked the previous neonatologists. 
Follow-up questions were also asked such as the benefits of breastfeeding and how it 
helps in the recovery of the infant. We also discussed the different medications that the 
moms are prescribed during pregnancy which help with the withdrawal symptoms they 
experience when they come off the substance they were abusing. Likewise, I took field 
notes throughout this process. Afterwards, I observed her as she cared for an infant that 
had been exposed to drugs in utero but never developed signs of withdrawal. She brought 
the baby back to the room where the mother was staying and did a lactation consultation. 
She explained how to properly breastfeed the baby and encouraged her to do so; 
however, she also assured her that it was perfectly normal if she was not able, or it was 
too difficult. The mother was having a difficult time trying to get the baby to breastfeed, 
but the lactation consultant gave her advice on how to increase production of milk and 
how to get the baby to latch to feed for a sufficient amount of time. Although this baby 
had not been diagnosed with NAS, this experience was very helpful in my understanding 
of the care for drug-exposed infants. During my observation, I did not observe any 
interactions between providers and infants formally diagnosed with NAS.  
To analyze the data obtained from the observations/interviews, I initially read all 
my field notes and the documents received after the observations at each hospital. I then 
identified three specific themes that were prominent at each hospital. These themes 
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include both pharmacological and nonpharmacological treatments as well as 
advocacy/community resources. After I determined the broad, overarching ideas, I 
conducted a detailed analysis based on each specific theme. The detailed analysis 
includes examples such as quotes and stories and generalizations for each topic based on 
my observations, interviews, and document reading.       
I could not find a clear, exact treatment protocol for NAS that was issued by a 
national organization/association; however, I did find three national organizations that 
released treatment guidelines/position statements. I conducted a web search of various 
national medical organizations and Neonatal Abstinence Syndrome to see if any 
guidelines had been posted for that particular organization. I then followed several of the 
supporting articles that had been cited for additional information. These three 
organizations and their guidelines/position statements are addressed in the “Findings” 
chapter.      
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FINDINGS 
 Throughout my observations, interviews, and document reviews, I was able to 
identify five main themes related to Neonatal Abstinence Syndrome (NAS) that were 
apparent in all three NICUs. Although the protocols were somewhat varied, each NICU 
has a treatment plan in place that includes morphine as the first line of treatment if 
pharmacological measures are needed. Likewise, each NICU implements 
nonpharmacological measures first, if possible, to prevent the infant from being subjected 
to narcotics. These protocols witnessed during the observations were compared to 
treatment guidelines issued by three national medical organizations. Lastly, there are 
community resources available for mothers struggling with opioid addiction who have 
recently given birth to an opioid exposed infant. As well as helping connect mothers with 
nearby resources, healthcare practitioners are fervently advocating for a national 
standardized treatment protocol for NAS which would help healthcare professionals 
across the country better treat infants diagnosed with this disease.  
Nonpharmacological Treatment 
Based on my observations and literature research, there seems to be a consensus 
that the first line of treatment for NAS should be nonpharmacological measures if 
possible. However, if the infant has extreme withdrawal and receives a high score on the 
NAS Scoring Sheet, nonpharmacological measures are not sufficient, and medication will 
be used to try and alleviate the symptoms. There are many different techniques that can 
be used to administer nonpharmacological treatment, but the main goal is to reduce 
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stimulation and light exposure and provide adequate comfort and support for the infant 
(Hudak, Tan, The Committee on Drugs, & The Committee on Fetus and Newborn, 2012). 
According to Neonatology for Primary Care, only 25% of infants who display 
withdrawal symptoms will need pharmacological treatment (Ostrea, Alviedo, Banadera, 
Cortez, & De Jesus, 2015, p. 469); therefore, it is extremely important that supportive, 
nonpharmacological treatments are readily available and implemented properly.    
All three NICUs in question agreed that nonpharmacological measures should be 
implemented first before medication is considered. These measures include but are not 
limited to skin-to-skin contact, breastfeeding, reduction in stimuli (light, touch, and 
sound), skin protection, and swaddling. The second hospital I observed in provided me 
with the information pamphlet they provide to the parents. The recommendations they 
provided include keeping the lights low, turning off the TV, setting any phones to a low 
ring or silent, touching the baby gently and speaking in a low voice, keeping visitors to a 
minimum, waking the baby only for feeding, and caring for the baby without a lot of 
handling or touching. The pamphlet also recommended using skin-to-skin contact and 
swaddling. The second hospital I observed at also stated that the practice of rooming-in 
has been very effective. The rooming-in approach allows the mother to bond with the 
infant and learn how to properly care for her infant. The lactation consultant I shadowed 
noted that “keeping the mom and baby together increases bonding and helps mom feel 
needed, necessary, and successful.” While shadowing the lactation consultant, she was 
caring for an opioid-exposed infant and was encouraging the mother to attempt 
breastfeeding and keep the baby with her as much as she could. She explained the 
benefits of skin-to-skin contact and breastfeeding and that these were extremely helpful 
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in preventing withdrawal symptoms for the baby. The nurse I interviewed from the rural 
hospital agreed that she thinks the rooming-in approach would work well in her hospital. 
This hospital does not currently implement this practice. The first hospital I observed at 
also implements the rooming-in approach as long as the infant does not require any acute 
care which would require him/her to be placed in the NICU. All three hospitals treat 
infants with nonpharmacological measures as a first line of treatment before medication 
is used. Pharmacological treatments are used only when nonpharmacological treatments 
are unsuccessful in maintaining the infant’s withdrawal scores at a low level.  
Although there is no standardized treatment plan for NAS, each hospital I 
observed agrees that nonpharmacological measures should be taken before any 
medication is prescribed to alleviate withdrawal symptoms. There is not one single 
method that works best for this first line of treatment; it is simply based on placing the 
infant in a low stimulation environment that will nurture and promote infant growth and 
comfort. 
Pharmacological Treatment 
Pharmacological treatment of NAS includes medications prescribed to infants 
who express symptoms of withdrawal to help reduce the effects which can be fatal. 
Medications used to treat NAS are opioids (tincture of opium, neonatal morphine 
solution, methadone, and paregoric), barbiturates (phenobarbital), benzodiazepines 
(diazepam, lorazepam), clonidine, and phenothiazines (chlorpromazine) (Hudak et al., 
2012). Morphine, clonidine, and phenobarbital were all included in the treatment 
protocols I received from the hospitals I observed. There is currently no standardized 
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treatment protocol for NAS to guide healthcare practitioners on which medications and 
dosages to prescribe (Patrick et al., 2014).  
While interviewing the various healthcare practitioners and reading the 
documents/protocols given to me, I noticed a stark similarity between the hospitals’ 
pharmacological treatment plans. The nurse I interviewed from the rural women’s 
hospital gave me a copy of the hospital’s protocol for assessment and treatment of NAS. 
They use the Modified Finnegan Neonatal Abstinence Scoring Tool which the other 
hospitals use as well. The Modified Finnegan Scoring Tool measures three different areas 
of the infant’s overall health including central nervous system/neurologic excitability, 
autonomic signs, and gastrointestinal dysfunction. CNS/neurologic excitability includes 
tremors, irritability, increased wakefulness/sleep disturbance, high-pitched crying, 
increased muscle tone, hyperactive deep-tendon reflexes, seizures, frequent yawning and 
sneezing. Autonomic signs include sweating, nasal stuffiness, fever/temperature 
instability and mottling. Poor feeding, uncoordinated and constant sucking, vomiting, 
diarrhea, dehydration, and poor weight gain are symptoms of gastrointestinal 
abnormalities.  The infant is scored every three to four hours. Morphine sulfate is given if 
two consecutive scores are greater than 8. The first hospital I observed in also 
implements oral clonidine if morphine alone is not sufficient. The second hospital I 
observed also initially uses morphine and adds oral clonidine then phenobarbital if 
morphine alone does not help lower the infant’s scores. 
At the first NICU I observed, there was an infant who had to be scored using the 
NAS tool during each of the baby’s care sessions. This particular baby did not have NAS 
but had to be treated with narcotics due to prolonged ventilation. The nurse scored the 
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baby by examining him while she changed his diaper and made sure he was comfortable 
in his crib. I watched as she charted and scored him using the electronic score sheet. The 
baby was not very fussy and had not been displaying signs of withdrawal; therefore, he 
was not given any narcotics at that time.     
Based on my observations/interviews, morphine seems to be the most common 
medication prescribed to infants experiencing drug withdrawals. However, the hospitals 
use different secondary medications if the first line of pharmacological treatment is 
insufficient. Considering the recent increase in NAS, there is a dire need for a national 
standardized medication protocol that is implemented by each hospital. Without a 
national standardized protocol, treatments and clinical outcomes may vary widely across 
hospitals in the U.S. (Hearing on H.R. 1462, 2015). 
Discharge Policy 
During my interviews and observations, specific details regarding discharge were 
never fully discussed, but the general process was laid out. According to my interview, 
the rural hospital typically discharges the patient from the NICU within two to four 
weeks, and the patient follows up with a pediatrician or the NICU outpatient clinic, 
depending on the physician’s orders. The first hospital I observed discharges infants after 
they have stopped pharmacological treatment, and the infant scores below a certain 
number on the NAS scoring form. The baby is then seen in the new baby clinic within 
48-72 hours after discharge while also following up with a pediatrician. Discharge policy 
was not discussed at the second hospital I observed in.    
The American Academy of Pediatrics’ (AAP) Committee on Fetus and Newborn 
released proposed guidelines for hospital discharge of the high-risk neonate in 1998 and 
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again in 2008. The 2008 guidelines were reaffirmed in 2011 (AAP, 2012). There have 
been no recent guidelines published since then. In the 2008 guidelines, the AAP 
classified infants with parents who committed substance abuse as high-risk infants due to 
family issues. The guidelines proclaimed that the infant was put at higher risk due to 
“adverse effects on the developing fetus in utero and because of possible postnatal 
exposure to drugs through breastfeeding or by inhalation” (Committee on Fetus and 
Newborn, 2008, p. 1121). The behavior of the parents was also concern for the child’s 
home environment. The Committee stated that effective strategies for ensuring the safety 
of the infant have been difficult to find. Most of them have included follow-up 
observations such as home visits; however, the success of these visits is not entirely 
evident (Committee on Fetus and Newborn, 2008). Although parental drug use is 
mentioned in the article, there is no mention of NAS. This lack of literature on discharge 
of NAS infants by the AAP is further proof that more research is critically needed.    
National Organizations’ Guidelines/Position Statements 
Just as the treatment protocols of the hospitals I shadowed in vary, the 
guidelines/position statements of national medical organizations differ, as well. The 
National Perinatal Association (NPA) issued a position statement in 2017 concerning 
NAS treatment. The position statement expressed support for comprehensive treatment 
programs for parents and encouraged continued research of rooming-in practices for 
mother and infant. The NPA also encouraged health care access with prenatal and 
substance abuse treatment in one facility (Goyer, Hoppe, Milford, & Puccio, 2017). The 
AAP issued a policy in 2012 expressing support for the modified Neonatal Abstinence 
Scoring System which assesses twenty-one different symptoms/signs that are observed 
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during presentation of NAS. The AAP stated that infants at risk for NAS should be kept 
in the hospital and observed. The length of stay is variable and depends on the mother’s 
substance use history. The first line of treatment should be nonpharmacological measures 
aimed at reducing stimulation and maximizing the infant’s comfort. Breastfeeding is also 
encouraged in that it has been “associated with less severe NAS that presents later and 
less frequently requires pharmacologic intervention” (Hudak et al., 2012, p. 548). The 
AAP urges every nursery to have a NAS protocol and to train staff on how to properly 
conduct a NAS assessment. The AAP does not encourage pharmacological treatment 
unless the infant has failed to respond to nonpharmacological treatments, and medication 
is deemed absolutely necessary. It should be used in these cases to prevent complications 
such as fever, weight loss, and seizures. The AAP did not issue a precise protocol in this 
policy on which medication to use or dosage amounts. The policy stated that the majority 
of clinicians in the United Kingdom and the United States use an opioid (either morphine 
or methadone) (Hudak et al., 2012). In the AAP’s policy released in 1998, no dosage 
amounts were given for morphine; however, methadone was stated to be given in initial 
doses of 0.05 to 0.1 mg/kg every 6 hours, “with increases of 0.05 mg/kg given until signs 
are controlled” (Committee on Drugs, 1998, p. 1084).   
The Joint Commission also released an information piece on the management of 
NAS. The Joint Commission stated that the Finnegan Scoring System is widely 
recommended to assess infants’ withdrawal severity. Infants should be scored every 3 to 
4 hours until 48 hours after medication has been stopped. The Joint Commission also 
stated that breastfeeding support should be given, and if possible, rooming-in should 
occur. The organization agrees that pharmacological treatments are only to be used when 
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nonpharmacological measures have not been sufficient and/or the infant is experiencing 
severe complications. The document states that “no single medication or regimen is 
considered suitable for every patient,” and “there are no standardized regimens for 
pharmacological management of NAS” (The Joint Commission, 2016, p. 1-2). The Joint 
Commission also maintains that morphine is the most common drug used to treat NAS. 
They issued that the goal for NAS management is for infants to exhibit normal eating and 
sleeping patterns, weight gain, maintenance of stable withdrawal scores, and termination 
of withdrawal symptoms (The Joint Commission, 2016).     
Advocacy/Community Resources 
Because there is currently no standardized treatment protocol for NAS, the 
interviewees agreed that advocacy for legislative changes is essential in creating and 
passing a national standard for the treatment of NAS. Accessibility of community 
resources is also very crucial in providing adequate support for mothers and discharged 
infants who have no safe environment to return to. Both of these aspects combined can 
lead to a brighter future for both infants diagnosed with NAS and the mothers of these 
babies.    
Community resources play a vital role in helping suppress the rise in diagnosis of 
NAS. Addiction treatment programs and rehabilitation homes are crucial in helping 
women suffering from drug abuse and infants who have been diagnosed with NAS. The 
Rainbow (Residential Rehabilitation for Pregnant and Postpartum Women) Program is a 
great example of a community resource aimed at helping these two populations. The 
Rainbow Program employs licensed professionals who specialize in addiction treatment 
and pre- and post-natal care. They also offer a wide variety of services that include 
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residential and outpatient treatment and many social and physical amenities such as food, 
clothing, shelter, transportation, and training/counseling (Meharry Medical College: 
Rainbow, n.d.).  
Advocacy and community resources are two essential aspects of helping alleviate 
the surge in opioid-exposed and NAS diagnosed infants. With the help of healthcare 
practitioners and rehabilitation programs, hospitals across the country may one day 
implement a national standardized treatment protocol as well as see a decline in the 
number of infants exposed to opioids.  
Fetal Alcohol Syndrome: Aid in Creation of NAS Protocol 
Although NAS does not have its own national standardized protocol, there are 
guidelines for other infant diseases such as Fetal Alcohol Syndrome (FAS). To help in 
the creation and development of a protocol for NAS, it might prove helpful to look at 
these other guidelines and gather information such as formatting and diagnostic 
requirements which could aid in the writing of a NAS protocol.   
In 2002, U.S. Congress mandated that the Centers for Disease Control and 
Prevention (CDC) acting through the National Center on Birth Defects and 
Developmental Disabilities (NCBDDD) Fetal Alcohol Syndrome (FAS) Prevention Team 
and in coordination with the National Task Force on Fetal Alcohol Syndrome and Fetal 
Alcohol Effect (NTFFAS/FAE), other federally funded FAS programs, and appropriate 
nongovernmental organizations would develop guidelines for the diagnosis of FAS, 
incorporate these guidelines into curricula for students in medical programs and 
practitioners, seek to have them recognized by professional organizations and accrediting 
boards, and distribute curricula to and provide training for students and practitioners 
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regarding these guidelines. The diagnostic criteria were developed over a two-year period 
and includes facial dysmorphia (smooth philtrum and thin vermillion border ranking 4 or 
5 on the University of Washington Lip-Philtrum Guide and small palpebral fissures at or 
below 10th percentile), growth problems (confirmed prenatal or postnatal height or weight 
at or below the 10th percentile), and Central Nervous System abnormalities (structural, 
neurological, and/or functional). For an infant to be diagnosed with FAS, the infant must 
display and have documentation of all three of the above defects. These guidelines were 
created to ensure a more consistent diagnosis of FAS (NCBDDD, CDC, & HHS, 2004). 
The early development of the CDC’s protocol for FAS resembles the stage in 
which NAS is currently experiencing. When this report was first published in 2004, there 
were no proper criteria for diagnosing FAS and there was a “lack of knowledge and 
misconceptions among primary care providers” (NCBDDD et al., 2004, p. 3). Many 
healthcare professionals believed the mother had to be an alcoholic for the baby to 
contract FAS. There were also misconceptions that FAS only occurs among low-income 
and/or racial minority groups (NCBDDD et al., 2004). As with NAS, this is not true. For 
example, NAS does seem to occur more frequently in rural areas which may be low-
income but occurs predominantly in Caucasian households. FAS is also difficult to 
distinguish from other alcohol-related conditions (NCBDDD et al., 2004). As with NAS, 
the diagnosis can oftentimes be tricky due to the spectrum of conditions that each entails. 
For example, a baby that experienced prenatal drug exposure may show no signs of drug 
withdrawal throughout the hospital stay; therefore, the infant is not diagnosed with NAS. 
However, he/she could potentially begin withdrawing after discharge.  
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After Congress mandated that FAS guidelines be issued for diagnosis, the CDC 
created an internal team that conducted preplanning meetings to help develop the best 
way to create all aspects of the guidelines. Each aspect of the guidelines was created by 
reviewing literature and having discussions with consultants, clinicians, researchers, and 
parents of affected children (NCBDDD et al., 2004). If these steps were taken, the 
medical community may be able to develop a standardized NAS protocol that could be 
implemented across the country and that it would lead to a more consistent diagnosis and 
treatment of NAS. 
There are three basic steps for the diagnosis of FAS and include initial 
identification, referral, and diagnosis. Initial identification for FAS may be recognized 
later in life during early school-age years. Parents may recognize differences between the 
child and siblings or daycare staff may notice the child experiencing difficulty. 
Pediatricians are also some of the first to detect and screen for problems. Obstetricians 
may refer a newborn if they suspect the mother may have a substance abuse problem. 
Unlike FAS, symptoms of NAS are recognized within the first few hours of life until 
approximately six months of age.  
After a clinician begins to suspect an alcohol-related disorder, he/she will gather 
the necessary documentation and may refer the child to a multidisciplinary team for a 
confirmed diagnosis. The team will then diagnose the child using more thorough FAS 
diagnostic procedures to evaluate dysmorphia and growth parameters as well as look at 
neurodevelopmental evaluation data. Likewise, to diagnose NAS, healthcare practitioners 
use the NAS scoring sheet to monitor and document the presence and/or severity of the 
infant’s withdrawal symptoms.  
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When the child is officially diagnosed with FAS, a plan is developed and includes 
many specialists such as dysmorphologists, developmental pediatricians, psychiatrists, 
psychologists, social workers, and educational specialists (NCBDDD et al., 2004). 
Similarly, an infant diagnosed with NAS has a team of specialists including social 
workers, lactation specialists, child life specialists, and speech, occupational, and 
physical therapists; however, it is unclear how long the infant has these services.  
Once an infant with NAS is discharged, they are typically seen in a follow-up 
clinic for developmental concerns. If developmental deficits or physical abnormalities are 
observed, it is often difficult to distinguish which substance is the specific cause due to 
many mothers using multiple drugs including alcohol, tobacco, and prescription and/or 
street drugs; therefore, it is oftentimes unclear which drug causes which 
symptoms/deficits. For example, infants exposed to alcohol and methadone, a 
replacement drug often prescribed to pregnant women to lessen use of other opiates and 
illicit drugs, failed to habituate to a novel tone at 7 months of age; however, infants 
exposed to methadone alone did not demonstrate this pattern. According to researchers, 
opioid-exposed children scored significantly lower on the Mental Development Index 
(MDI) at 12 and 18 months. Infants exposed to methadone were also found to display 
“increased motor rigidity, dysregulated motor patterns and decreased activity” (Logan, 
Brown, & Hayes, 2013, p. 189). Additional studies are still needed to further identify and 
confirm specific long-term developmental outcomes for opioid-exposed infants.               
 32 
DISCUSSION 
 There is no standardized treatment protocol for NAS; therefore, it is critical to 
understand how healthcare practitioners are treating these patients as well as navigating 
the various treatment guidelines issued by national medical organizations. According to 
my findings from the observations, interviews, and document reviews, it is clear that 
there is an evident need for a standardized treatment protocol. Although all three NICUs 
had a different treatment protocol for infants diagnosed with NAS, they all contained 
many similarities and closely resembled the guidelines issued by the national medical 
organizations. However, the lack of a standardized protocol is apparent and could be 
contributing to possible variations in patient treatment and outcome. Morphine was the 
first line of treatment for all three units, but they varied in the second line of medication. 
The lack of documents on dosage for the medications is also a concern for the need of a 
standardized protocol especially for units who may not experience a frequent number of 
infants with this disease. With a national protocol, there would be less uncertainty on the 
right plan of treatment, and regardless of unit location, each infant would receive the 
same care based on his/her condition.    
Variation in the nonpharmacological treatment such as the placement of the 
infant, whether it be with the mother or in the NICU, is also a concern for 
standardization. Studies have shown that the practice of rooming in is beneficial for both 
mother and baby. If all units were required to implement this practice, healthcare 
practitioners may see a reduction in the length of stay and in the number of patients who 
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require medication. This would also remove all patients from the NICU which is not the 
best place for a NAS infant to properly heal and recover. If acute care is not needed that 
would require the infant to be placed in the NICU, the infant should be placed in a quiet 
room, if possible. Oftentimes, the NICU is a bright, loud environment filled with a 
multitude of people and lots of beeping noises. If the patient was placed in a room with 
the mother, the baby would be in the ideal environment to heal as well as have the 
opportunity to bond with the mother.  
A standardized protocol should also have other nonpharmacological treatments 
outlined such as the 4moms mamaRoo. The mamaRoo has shown to calm fussy infants 
experiencing withdrawal symptoms and is useful when the parents are not present and the 
healthcare provider is unable to rock/soothe the baby. The mamaRoo looks promising; 
however, additional studies are warranted to further prove its effectiveness. The company 
offers a product discount to hospitals and health care centers and is currently used in over 
350 maternity wards, NICUs, and pediatric units across the U.S (4moms & NPA, 2018). 
Having a standardized protocol that included nonpharmacological treatments would help 
guide healthcare practitioners on the right plan of action and would ensure that the infant 
received the best care available.    
Other protocols, such as Fetal Alcohol Syndrome (FAS), should be looked at to 
help in the creation of a standardized NAS protocol. Just as FAS was once addressed as a 
phenomenon in need of diagnosis and treatment protocols, the treatment of NAS is 
experiencing some of the same struggles as the treatment of FAS once did. Lawmakers 
and healthcare practitioners could gain useful insight by looking at the development and 
creation process of the FAS treatment protocol and lessons learned from such efforts. In 
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order to create a protocol that will be implemented accurately and treat babies affected by 
NAS successfully, there needs to be a variety of people with different perspectives and 
backgrounds involved in the development process. During the creation of the FAS 
protocol, many people gave their insight and knowledge to help create the protocol. 
These people included clinicians, researchers, parents of affected children, and many 
more. The development process could benefit greatly if similar groups of people were 
used in the creation of a NAS protocol.          
 There were several limitations to this study as well as ways in which this study 
could be improved. Because I conducted personal observations and interviews, the 
number of NICUs I was able to observe was low. In contrast, if someone performed a 
survey concerning the treatment plans of NICUs, he/she would be able to collect data 
from units across the country. This would give the researcher a much larger pool of data 
from which to compare the protocols and would give a better image of how varied 
treatment protocols are across the nation. However, this particular study was very 
intimate, and I was able to personally observe the different treatment protocols in action. 
The rich data this kind of observational and interview study provides, it can provide 
insights that a survey alone would miss.   
 The information gathered in this study could help inform the creation of new 
policies to not only implement a national standardized treatment plan but help lawmakers 
decide on which plan of care to include that would best treat this disease. This study also 
sheds light on the gaps that are present in this area of research. More research needs to be 
conducted on the causes of the recent increase in NAS and why, in particular, rural areas. 
Healthcare practitioners should also be more involved in the legislative process and 
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inform law makers of implemented protocols that are achieving success in their own 
hospitals.   
 Neonatologists who are involved in the research and practice of treating NAS are 
fervently advocating for a national standardized protocol for NAS treatment. Healthcare 
practitioners such as Drs. Stephen Patrick, Sean Loudin, and Tony Napolitano are 
researching, advocating for, and developing guidelines for the treatment of NAS. Dr. 
Stephen Patrick’s research is funded by the National Institute on Drug Abuse and focuses 
on “improving outcomes for opioid-exposed infants and women with substance-use 
disorder and evaluating state and federal drug control policies” (Vanderbilt University 
SOM Faculty Profiles, n.d., p. 1). He has served as Senior Science Policy Advisor to the 
White House Office of National Drug Control Policy and has testified before Congress 
on the recent increase of infants being diagnosed with NAS. During his testimony before 
Congress, he explained the results of the recent opioid epidemic which has led to an 
increase in the number of opioid-exposed infants. Due to the lack of a standardized 
national protocol for NAS treatment, there is a wide variation in treatment and clinical 
outcomes throughout hospitals in the US. The Protecting Our Infants Act of 2015’s 
primary goal is to help people better understand the problem and fill knowledge and 
service gaps (Hearing on H.R. 1462, 2015). The Act asks the Department of Health and 
Human Services (HHS) to “conduct a study and develop recommendations for preventing 
and treating prenatal opioid abuse and neonatal abstinence syndrome” and calls on the 
Centers for Disease Control and Prevention to “coordinate and improve surveillance 
systems for NAS and to craft a public health response to the syndrome” (Hearing on H.R. 
1462, 2015, p. 5-6). Former President Barack Obama signed the bill into law on 
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November 25, 2015. In a report to Congress released in 2017, the HHS recommended 
that evidence-based protocols be established to identify and manage NAS and that 
breastfeeding and nonpharmacological treatments be promoted. The strategy developed 
by the HHS, once finalized, will be used to inform policy and planning; however, full 
implementation will be contingent upon funding (Behavioral Health Coordinating 
Council Subcommittee on Prescription Drug Abuse, 2017). Without the research and 
advocacy of healthcare practitioners like Dr. Patrick, the bill’s passage would not have 
been likely.  
 NAS is a unique disease in that it was internally created by the healthcare industry 
itself. If physicians had never been pushed to prescribe opioids in excess, NAS may have 
never been a nationally recognized phenomenon, and the need for a national standardized 
protocol would be nonexistent. Because of its peculiar history and origin, the research 
approach used for this particular disease could be applied in the research of other medical 
illnesses. Additional analysis and research using this approach could lead to valuable 
insight into many other areas of disease in medicine.  
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APPENDIX 
Interview Questions  
1. Are you over the age of 18 and consent to the observation/shadowing and 
interview as described in the information sheet? 
2. What percentage of infants admitted to this hospital are diagnosed with Neonatal 
Abstinence Syndrome (NAS)? 
3. Are these infants placed in the Neonatal Intensive Care Unit (NICU)? If not, are 
they placed with the mothers, in the nursery, etc.? 
4. What is the standard treatment protocol, and are any experimental options, such as 
music therapy, being implemented? 
5. What do you think is the best treatment plan for an infant diagnosed with NAS? 
6. Does this hospital implement the “rooming-in” approach? If so, do you think this 
method has improved the quality of life for the baby, the mother, or both? 
7. Considering many babies admitted to the NICU are transferred from another 
hospital, do a disproportionate number of these patients come from a particular 
area or region? 
8. What factors do you think contribute to the recent increase in NAS, specifically in 
rural areas? 
9. Do these infants experience any developmental complications in early childhood 
due to NAS? 
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10. After the patient is released, what kind of outpatient care does the infant receive, 
if any? 
11. Do the infants have varying intensities of NAS depending on which drug the 
mother was taking? If so, which drug causes the most severe degree of NAS? 
12. Are there any complications in pregnancy, in utero, or during birth related to 
NAS? 
